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Chapter 1: The prevalence of plakophilin-2 gene mutations in South 
African patients with cardiomyopathy 
1.1 Structure of the heart 
The wall of the cardiac chambers is composed of three layers: the epicardiwn, 
myocardium and endocardium which are surrounded by the pericardium (figure 1). 
The cells of the myocardiwn are striated and contain actin and myosin filaments that 








Le yers of ttl 
Figure 1: A section of the heart wall from the right ventricle 
Contractile force generation of sarcomere and its transmission to the extracellular 
matrix are the fundamental functions of the myocardium. Disease affecting the 
myocardiwn leads to cardiac remodelling by hypertrophy or dilation or both (Morita 
et at. 2005). Cardiac dysfunction may lead to arrhythmia, heart failure, and death. 

























wn(health.yahoo.com/ .. .!healthwise/popup/hwI41771 ) 
Figure 2: A post mortem section of the right ventricle showing the iniiltration of the 
right ventricular myocardium by fatty tissue in a case of ARVC. 
ARVC is associated with re-entrant tachyarrhythmias of right ventricular origin and 
the risk of sudden death in young people and athletes. In ARVC, the disease affects 
the free wall of the right ventricle with sparing of the septum and progresses from 
epicardial to the endocardial surface of the myocardium. The fibro-fatty infiltration is 
said to affect mainly the apical, subtricuspid and infundibular regions of the right 
ventricle (Michael et al. 2004). There is increasing recognistion that the disease 
process also affects the left ventricle in a significant proportion of cases of ARVC 
(Gerull et al. 2004; Norman et al. 2005). The previous reports considered ARVC as 
the abnormality of development of the right ventricular myocardium (thus the 
previous term 'dysplasia') but the recent information suggests that ARVC results from 
progressive, non-ischaemic loss of myocardium with the replacement by adipose and 
fibrous tissue (thus the term 'cardiomyopathy is preferred) (Michael et al. 2004). 
The aetiology of ARVC is not fully understood. The disease is familial in 50 -70 % of 
affected individuals and sporadic in the rest of cases. It is thought that the disease 
results from an inheri ted or acquired insult that causes cardiac cell apoptosis and 
replacement by fatty tissue or fibrosis. The prevalence and incidence of the disease in 











accounts for 3-5% of unexplained sudden death in people under the age of 65 years 
(Moolman-Smook et al. 2003). 
DCM is characterized by dilatation of all cardiac chambers and reduction of the 





(Indik et al. 2003) 
Figure 3: Comparison between normal heart and a heart with DCM 
DCM in most cases presents with progressive heart failure. Thrombosis and 
arrhythmias may occur at any stage and are not uncommon in this type of disease 
(Richardson et al. 1996). DCM may be idiopathic, familial, viral, auto-immune 
(Caforio et al. 1994, Kilhl et al. 1996), alcoholic/toxic or associated with recognized 
cardiovascular disease in which myocardial dysfunction is not explained by the 
abnormal loading conditions or extent of ischemic heart disease (Richardson et al. 
1996). DCM has a prevalence of 112,500 individuals and the incidence of 7/100,000 
per year (Codd et al. 1989). 
1.3. Clinical diagnosis of ARVC and DCM 
In 1994 McKenna and his colleagues proposed the diagnostic criteria for ARVC 
(McKenna et al 1994). In 2003 Ahmad came with a recent version of diagnostic 
criteria (tablel). Both diagnoses are based on the presence of major and minor criteria 
that encompass electrocardiographic disturbances, structural and functional 

































Global and! or and structural alterations 
Severe reduction and dilatation of 
ventricular ImlpalJrnHmt. 
ventricular p,,,,,rn'ln fraction with no left 
Localized ventricular aneurisms. 
Severe se~\mlmt:al dilatation of the ventricle, 
Minor: Mild 
normal left ventricle, 
ventricular dilatation and! or reduced fraction with 
Mild segmeJlltal dilatation ventricle. 
""i".,..nifi:lttv r~:pUlcelrneJm of heart muscles cells on 
and individuals 
of the 
ventricular tl'l,..hv,rl'l,..tiil'l ( sustained and nOltlSllLStalt 
Familial disease confirmed at necropsy or surgery 
sudden death due to 
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DSP· DesmopJakin; DSC-2 - Desmocollin-2;1UP- Junctional plakoglobin;DSG-2 -DesmogJobin-2; 
PKP-2 - Plakophilin-2 (Sen-Choudry S el al. 2007) 
Figure 5: Schematic of desmosomes structure 
Desmosomes serve as anchoring sites for rope-like intermediate filaments that form a 
structure of great tensile strength (Alberts et al. 2002). Desmosomal proteins also play 
a role in cell signalling (Gerull et al. 2004). Desmosomes are abundant in tissues that 
experience mechanical stress, such as the heart and the skin. This proposal is 
supported by the existence of diseases in which tissue integrity is destroyed by gene 
defects or by autoimmune antibodies targeting desmosomes (Green et al. 2000). 
1.8 Mechanism of disease due to desmosomal protein defects 
There are several hypothesis that have been proposed to account for the 
cardiomyopathies that are associated with defects in desmosomal proteins. The 
desmosomal model of ARVC proposes that the compromise of the desmosome leads 
to detachment and death of affected cells of the heart. Myocardial regenerative 
capacity is limited, resulting in fibro-fatty replacement of affected myocardium 






























DNA Race Gender 
ACM 1.2 Male 
ACM2.4 Male 
ACM3.1 Female 
ACM4.1 26 Female 
ACM5.1 44 Caucasian Female 
ACM6.1 52 Mixed Male 
ACM 8.3 14 Caucasian Female 
ACM 9.1 27 Caucasian Male 
ACM 10.1 39 Mixed Male 
ACM 11.2 15 Mixed Male 
ACM 12.1 50 Caucasian Male 
ACM 13.1 18 Caucasian 
ACM 14.1 45 Mixed
ACM 15.1 27 Caucasian 
ACM 16.1 35 Caucasian 
ACM 17.1 22 Black 
ACM 18.1 21 Caucasian 




























DCM 128.1 42 Female 
OCM 136.1 55 Female 
OCM 175.2 29 Male 
• FDC 1.1 21 Male 
FDC 9.1 21 Male 
i DCM219.6 14 Male 
. DCM226.1 4 Male 
DCM236.2 4 Male 
OCM 240.1 Female 
DCM241. Male 
DCM242.2 Female 


























P;-um::r Primer sequence (5 '-3 ~"'Yv ~,ur/:; 
Size (bp) 
IIF 
· ACT CGA GCG GGG CGG GGC TCG C 
I 414 68 
I 1R ACT CCC AGC ACG CGG GGT GAG 
.2F TAC TTG TTC TTG GCC TTC ATT AC 55 
2R 332 ACT TGG GAA AAG TAA ACA CTC 
J 
3Fl i AGTCCTCAGCAAAGTTGAAATTTG 53 
3Rl 423 GTCAAAAACGGTGTCGCTAACAGA 
·3F2 CACATACCACAGACAGTACCAG 58 
·3R2 433 TGTGCTGGCAATGACTGAACTG 
·4F I · AGT ATT CGC TGA GTC GTC TCT 55 
4R 291 I GCA AAG TCA CCA TAA TAG AAG 
I 
5F GAAAGGTTATAGTCAGCATCAG 55 
· 5R 413 I CAT CAA TCA TTT GCT CCA GGA 
6F · TTG CTG TGT TCA TAA AGG AGC C 55 
6R 258 ATT ACA GGC GCA GAC CAC GAC A 
.7F TCC AGC GGT CAT TIT GGT CCC A 55 
· 7R 305 ! TGA CTT CCT TGG GGC TAC CT A A 
I 
8F CAA AGA CCT GTT GGA TAC ACA 55 
8R 250 I CCAAGCGGCTATCTTAAGAAT 
9F I 493 · TAC TCA TTG CAT TTC CCC CAG 57 
9R TCC TCA CTG GTA AAT GAG GG 
lOF 458 CAG TAT TTC TGG TCT CCT GG 55 
I lOR TGA CTT GAC TTG TCA GTC AAG CAG CCT GAC 
lIF 417 ACA TCT TCA ACC TCT GGT AA T CTA CAG 58 
llR AGA AAG CCT GTT TGT GAT ATC TGG TGG CAC 
12F .402 · CAA CAG AGC AAG ATT CCG 58 
· 12R GTT GTG AA T GTG CGG TCA TG 
I 
13F 539 AGT TGA GGA GCG AAG GGG ACC AC 57 
· 14R TTC TGG A TT CAG GGG ACC AC 
*Number(l 9) denotes the exon; F= forward primer, R= reverse primer 
on an 




















94 5 minutes 
94 30 seconds 
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Figure 6: Illustrations of the fonnation of both the heteroduplexes and the 
homoduplexes in the process of denaturing high-perfonnance liquid chromatography. 
(Frueh and Noyer-Weidner, 2003) 
The method detects all types of nucleotide mismatches regardless of the position of 
the mismatch within the fragment. The W A VE® system of dHPLC operates in three 
different modes: partial denaturation, full denaturation and non-denaturation (Xiao et 
al. 2001). This study utilised the partial denaturation mode, as it is applicable to 
mutation detection. The separation chemistry in partial denaturation is based on 
primer sequence, the size and the melting temperature (Tm) of the PCR products. 
Once the PCR products are loaded onto the autosampler, they are passed through the 
separation cartridge by the mobile phase. 
2.3.1 W A VE® method creation 
DHPLC-based WA VE® system has the Wavemaker software programme; the 
programme was used to create methods for mutation detection for each PCR 
amplicon. Each method was designed with different temperatures to allow elution of 
the partially denatured PCR product through the separation cartridge. 
2.3.2 Heteroduplexing of the peR products 
The PCR products of DNA samples of the individuals affected with cardiomyopathy 
were mixed in equal volumes (1: 1 ratio) with PCR products from the DNA samples of 
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· >G80401A Reverse 
• aaCTGAATTGAATGTAGGTATGTCTA 
>C99354T Forward 
I Exon 11 
• ccacgtaatcCTGCAGAATGAAATTGGTGAGT 
I Exon 9 



















20 Blue- Green 
26 Red- Black , 
32 Black- Red 
I 
38 Blue- Red 
44 Blue- Green 
150 Black- Red 
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Chapter 3: Results 
3.1 peR Amplification of DNA samples from affected patients 
PCR product bands of the expected size and the appropriate brightness were obtained 
when the PCR product was electrophoresed on the agarose gel (Fig. 7). 
458bp's 
Figure 7: Illustration of PCR amplification of exon 10 of PKP-2 ge e in 11 control 
individuals. The expected product size of 458 bp is nm on an agarose gel, and 
corresponds to the correct size according to the DNA ladder. 
All exons were amplified successfully using the published and redesigned (i.e., exon 
12) primers. 
3.2 Mutation screening using W A VE® technology 
An abnormal W A VE® pattern/variation in a DNA sequence of an individual sample is 
present when a chromatogram presents with a different peak profile to the normal 
(wildtype) (figure 8) peak profile. The DNA of 46 individuals in our cohort 
(ARVC=26; DCM=19; RCM=l) was screened for variations on the WAVE® system. 
Abnormal WAVE profiles were found in 19 probands: ARVC (n=12), familial DCM 
(n=6), and RCM (n=l) which resulted in a total of 66 profile variations in exons 4, 9, 
10, 11, 13 and 14. The distribution of W A VE® profiles were as follows: three in exon 
4, two in exon 9, 16 in ex on 10, 13 in exon 11 and 32 in exons 13+14. As quite a 
number of the chromatogram profiles appeared to be duplications it was decided to 
sequence the chromatograms presenting with different peak profiles. This resulted in 
a decrease in the number of samples to be sequenced; from 66 to ten. 
Figure 8 illustrates a normal sequence represented by DNA sample RPD 16.9 
(population control), which was run concurrently with DNA sample of ARVC 











Figure 8 shows a three peak electropherographic profile of ACM 1.2 produced by a 
WAVE run. The profile of ACM 1.2 is significantly different from the wildtype 
profile (i.e., three peaks in ACM 1.2 versus one peak in wild-type 16.9 at the elution 
time of 3 minutes). 
The DNA samples from ARVC probands ACM 5.1, 8.3,12.1, and 19.2 also had a 
similar chromatographic profile to ACM 1.2. These abnormal profiles do not 
necessarily indicate the same genetic mutation in PKP2. 
3.3 DNA sequencing analysis 
The abnormal WAVE@ electropherograms of the 19 probands (ten profiles) 
investigated were sequenced and the results summarised in Table 13. Our study has 
identified three known variants (two disease-causing mutations and one 
polymorphism) and seven novel variants (one disease causing mutation, six 
polymorphisms) in the PKP2 gene. These results are discussed in more detail below. 
31 
University of Cape Town
~~~::~~~~ 
No Nucleotide change Amico acid change niH"''' ''''lSI Patient ID 




Exonic 4 TlO94C M-T Polymorphism ACM 5.1, ACM 12.1, ACM 19.2 rslO46H6 
Intronic 10 IVS2146-1 G-C Intronic splice product Disease-cau sing ACM 22.1 Gerull et al.2004 
Exonic 11 2197-2202del -Stop Oi, ;inll 
~ 
ACM 19.2 Dalal et al 2005 
CACACCinsG 
Novel 
Exomc 4 C1l32T Q- stop ni~ lI<;inl1 ACM 1.2 -
Exonic 4 C1l62T R-W Disease-modifier ACM 5.1,ACM 12.1, ACM 19.2 
Intronic 9 IVS9+83C-G - Polymorphism ACM4.1 -
Intronic 10 IVSI0+44G- A - Poly "lUI .1'111"111 ACMQ.I ACM 20.1,DCM 10.3, -
DCM 226.1, FDC 1.1 & RCM 1.1 
Intronic 11 IVSll+7C- T - Polymorphism ACM 15.1 & DCM219.6 -
Intronic 13+14 IVS13+83G-A - D(JljU.VlpUI"UI ACM 6.1, ACM 8.3 ACM 18.1 & 
DCM3.5 
Exonic 13 T2540C L-P Rare rphism DCM3.5 
tth: ' ~l'Ircl Ivpdthy A;, .L cardiomvoDathv nmvnnl'lthv .p~ .. ly 
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3.3.2 Discovery of seven novel variants in PKP-2 
Sequencing of the abnonnal W A VE® electropherograms identified seven novel 
variants: one disease causing mutation and six polymorphisms in PKP-2. All of the 
sequencing results were heterozygous substitutions in the exonic or intronic regions of 
this gene. These findings are reported in relation to the affected regions as follows: 
In exon 4, we detected a C1132T polymporphism in PKP-2. The mutation alters a 
CAG codon to a TAG codon; the TAG codon codes for a stop in the translation of the 
protein. This disease causing mutation was found to occur in only one ARVC 
proband (ACM 1.2). When the Homo sapiens protein sequences was aligned and 




















Figure 10: In (A) an electropherograph of ACM 1.2 showing variant CI132T and 




























C T G AAGC T NG G AAGAGGG 
H. sapiens_ TFIQHECFQKSEAIKRVNQL 
C. lupus TFIQHECFQKSEA KRVNQL 
M. musculus_TFIQHESFQKSEA KRVNQL 
G. gallus_ TFIQHECFQKAEA RKVFSL 
Figure 12: In (A) an electrophorogram of ACMI9.2 showing the C1162T variant and 
(B) sequence alignment with other modem animals 
When the amino acid sequence from Homo sapiens was aligned with other modem 
animals it was found that the position of the C1162T is highly conserved through 
evolution (fig. 12B). Due to the highly conserved nature of this polymorphism we 
screened the family members of these three probands. It was however found that no 
extended families for ACM5.l and ACMI2.1 were available for screening. The 








































































Above exons SNPs 
Below exon Mutations 















3.4 SNaPshot results 
SNaPshot was used to genotype the background population (nonnal control DNA) in 
order to detennine the frequency of the seven new variants that were detected in this 
study. SNaPshot results were obtained through electropherograms with either 
homozygous or heterozygous peaks (figure 16). Heterozygous peaks confinned a 
polymorphismlSNP, while homozygous peaks represented the wildtype (nonnal). A 
negative control was included to eliminate the possibility of contaminants during the 
experiment. 




Figure16 : SNaPshot electropherogram of DNA from a control individual showing 
(1) a single blue peak for C 1162T (i.e., homozygous wild type), (2) a single red peak 
for IVSIO+44GA (homozygous wild-type), (3) two peaks for IVSll+7CT (i.e., 
heterozygote), (4) single blue IVS9+83GA (homozygous wild-type), (5) two peaks for 
IVS 13+83GA (heterozygote), (6) one peak for C 1132T (homozygous wild-type), and 
(7) one peak for T2540C (homozygous wild type). 
3.4.1 Frequency of mutations in common population groups 
The frequencies of the one known and seven novel variants were screened in three 
population groups, i.e., mixed ancestry, Blacks and Caucasians in order to establish 
their frequency in the South African background population. Tables 14 to 16 





































i Cl132T CIT 
C1l62T CIT 12 
IVS9+83C~G C/G 12 C 
IVSI0+44G~A G/A 12 G 
IVSll+7C~T CIT 12 C 
IVS13+83G~A G/A 12 G 
T2540C 
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T1094C PCM19_3 PCM19_6 
Cll32T 1 6 6 1 
Cl162T c T C T 
C C C c 
D12S1692 c c C T 
IVS9+83C-G 5 2 4 2 G G G G 
IVS IO+44G-C G G G G 
IVS2146-1 G-C G G G G G wr wr wr 
2196-2202de1CACACCinsG c c c c 
IVSl1+7C-T 
G G G G 
T T T T 
IVS 13+83G-A 1 1 1 1 
T2540C 
PCM19.4 ~M192 PCM19_5 PCM19_1 




T T C T T C C 
C C C C C C C 
C T C T C C C 
2 2 5 2 2 4 5 
G G G G G G G 
G G G G G G G 
G G G G G G G 
wr wr G wr wr wr G 
C C C C C C C 
G G G G G G G 
T T -.- -.- T T T 
1 1 WT-CACACC 1 1 1 
Figure 17: Haplotype results for ACM 19 family 
Genotyping of ACM5.1 and ACM12.1, who also carry the Cl162T variant, suggest 
























• • ACM5.1 ACM 12.1 
OJ2S2415474 6 1 
TI094C C T 6 1 
CI1321 C C C T 
CI1621 C T 
C C 
C T 
012S1692 4 2 9 2 
IVS9+83C-G G G G G 
I VS 1 O+44G-C G G G G 
1 VS2146-1 G-C G G G G 
2196-2202deICACACCinsG 
WT W W W 
C C C C IVSII+7C-T G G G G 
IVSI3+83G-A T T T T 
T2540C 1 1 
012S825316 
WT-CACACC 
Figure 18: Haplotype results for ACM 5-1 and ACM 12.1 
The absence of family information for individuals ACM5.1 and ACM 12-1, however, 
makes it difficult to be certain of the assignment of phase in these individuals. 
Nevertheless, the apparent occurrence of the C1162T variant on the same haplotype 
background in three unrelated affected individuals (ACM5.1 and ACM or potentially 
affected (ACM19_6) with ARVC raises the possibility of a founder effect, should the 
C 1162T variant be shown to be disease causing in functional studies. 
Haplotyping of the PKP-2 gene was also carried out in the DCM family with the 
T2540C to confirm that the affected individual who did not carry this rare variant (i.e., 
OCM 3.11) was related to the family (Figure 19), but did not inherit the haplotype 
carrying the rare variant from his mother (OCM 3.2). The lack of segregation of the 
T2540C with DCM in this pedigree makes it unlikely to be the disease-causing 
















13 DCM32 DCM3.3 DCM3.4 DCM3.9 6 DCM3.7 DCM3.1 
D12S1692 2 2 2 2 2 9 2 2 2 2 2 2 2 2 T T T T T T T T T T T T T T 
IVS9+83C-G C C C C C C C C C C C C C C 
IVSIO+44G-C 
C C C C C C C C C C C C C C 
4 6 4 6 8 4 3 3 7 5 4 6 8 6 
IVS2146-IG-C C C C C C C C C C C C C C C G G G G G G G G G G G G G G 
2196-2202de1CACACCinsG G G G G G G G G G G G G G G 
I VS II + 7C-IVS 13+83G-A 
wrwr wrwr wrwr wrwr wrwr wr 
C C C C C C C C C C C C 
T2540C A G A G G G G A G A G A C T C T T T T T T C T C 
DI2S825316 1 1 1 1 1 1 1 
DCM3.11 15 DCM3.12 DCM3.13 DCM3.6 
1 2 2 2 1 2 2 2 
T T T T T T ? T T C C C C C C C C 
C C C C C C 
DCM3.8 
C C 
8 4 7 6 7 6 6 7 
C C C C C C C C 
A G G G G G 1 2 G G 
G G G G G G T T G G 
wr wr wr wr wr wr C C wr wr 
C C C C C C C C C C 
G G G A G A 6 3 A G 
T T T C T C G G C T 
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V'OllUJ ..... 1: a COIlSel1t 
Division of Human Genetics 
lst Floor, Building 
TXT Medical Observatory 7925 
Tel: (021) 406 6425 Fax: (021) 448·0906 
PI"ase DO NOT send specimens on ice or frozen. 
Please fill in aU the infOrmation requested: 
New Family: [J No [J 
Medical 
M [J F [J Date _' ______ Month: _________ Day: ________ _ 
Ethnic Origin ( 
Fax: 
Referring Doctor/Sister: ___________ _ Town: Tel:~~~~~ __ 
Fax: 
Hospital or Address: ______ ~ _______ Town: ________ _ Tel: _______ _ 
Reason for Referral (Clinical diagnosis): 
Affected [J AtRisk [J Carrier IJ Spouse [J Query [J Unaffected [J 
Arrhvtilm,oqpnit'.Righl Ventricular [J 
Additional disorders (apparent or previously treated): ____________ ....................................................................... _____ _ 
Additional family history 
Clinical Details: 
Physical disability [J Mental retardation [J Deafness [J Impaired vision [J blindness [J 
Othcr: ................... ______________ ........ _______________________ _ 
Have samples from this palienl been senllO a DNA lab before? 
DNA number: 










I. , request that attempt 
made:u,:ini~g;;netiCm;;~i<llto~;esstli,;j;rob~lli);tb:atlmIlihtha~ii1h;eJitedl disease-causing mutation 
2. material for analysis is to be obtained from: blood cells/other (DELETE 




I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
(a) 
(b) 
( c) research purposes, 
Committee, provided 
I authorise I do not authorise my 
details to the Division onIuman 
to the approval of the 
any information from such 
care 
Town Research Ethics 
remain confidentiaL 
to: 






b) the eondition mentioned above and cannot determine 
the 
( ) the oh","n'.~~' is an VU1'5'''''VU 
(d) may not be informative some or family members. 
( e ) best conditions, current technology of this type is not perfect and could lead to 































































Appendix 3: GeneRuler™ lOObp DNA Ladder Plus 
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Appendix 4: mRNA sequence showing all exonic variants that are possible 
disease causing 
PKP2 plakophilin 2 [Homo sapiens] 
GeneID: 5318 Locus tag: HGNC :9024; MIM: 602861 
Official Symbol: PKP2 and Name: plakophilin 2 
updated 14-Apr-2005 
Transcripts and products: (shown on reverse complement genome) RefSeq below 
NL000012 
11 32940957 ] 11 32835055 ] 
5'~1 __________________________________________ ~13t 
NtL00 4572 I. II III I • NP 0045.,,3 
Genomic context: chromosome: 12; Maps: 12pl1 
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FGD4 CGI-04 LOC283343 SYT10 
DH"lL PKP2 .. ~ ---
The Sequence Manipulation Suite: Show Translation 
Results for 2646 residue sequence "NM_004S72" starting "atggcagccc". 
1 M A A P GAP A E Y G Y I R T V L G Q Q 
1 atggcagcccccggcgccccagctgagtacggctacatccggaccgtcctgggccagcag 
21 I L G Q L D S S S L ALP SEA K L K L 
61 atcctgggacaactggacagctccagcctggcgctgccctccgaggccaagctgaagctg 
41 A G SSG R G G Q T V K S L R I Q E Q V 
121 gcggggagcagcggccgcggcggccagacagtcaagagcctgcggatccaggagcaggtg 
61 Q Q T L ARK G R S S V G N G N L H R T 
181 cagcagaccctcgcccggaagggccgcagctccgtgggcaacggaaatcttcaccgaacc 
81 S S V P E Y V Y N L H L V END F V G G 
241 agcagtgttcctgagtatgtctacaacctacacttggttgaaaatgattttgttggaggc 
101 R S P V P K T Y D M L K A G T TAT Y E 
301 cgttcccctgttcctaaaacctatgacatgctaaaggctggcacaactgccacttatgaa 
121 G R W G R G T A Q Y S S Q K S VEE R S 
361 ggtcgctggggaagaggaacagcacagtacagctcccagaagtccgtggaagaaaggtcc 
1 41 L R H P L R R LEI S P D SSP ERA H 
421 ttgaggcatcctctgaggagactggagatttctcctgacagcagcccggagagggctcac 
161 Y T H S D Y Q Y S Q R S Q A G H T L H H 
481 tacacgcacagcgat taccagtacagccagagaagccaggctgggcacaccctgcaccac 
181 Q E S R R A ALL V P PRY A R S E I V 
541 caagaaagcaggcgggccgccctcctagtgccaccgagatatgctcgttccgagatcgtg 
201 G V S R AG T T S R Q R H F D T Y H R Q 
601 ggggtcagccgtgctggcaccacaagcaggcagcgccactttgacacataccacagacag 
221 Y Q H G S V S D T V F 0 SI P A N PAL 
661 taccagcatggctctgttagcgacaccgtttttgacagcatccctgccaacccggccctg 
241 L T Y P R P G T S R S M G N L L EKE N 
721 ctcacgtaccccaggccagggaccagccgcagcatgggcaacctcttggagaaggagaac 
261 Y L T AG LTV G Q V R P L V P L Q P V 
781 tacctgacggcagggctcactgtcgggcaggtcaggccgctggtgcccctgcagcccgtc 
281 T Q N R A S R SSW H Q S S F H S T R T 
841 actcagaacagggcttccaggtcctcctggcatcagagctccttccacagcacccgcacg 




















I ~ to I 













































I ~ to I 
2521 
• ~ to 
V G Q A A A G G S G N L L T E R S T F T 
gtcggccaggc ggccgcagggggaagtgggaatctgctcactgagagaagcactttcact 
o S Q L G N ADM E M T L ERA V S M L 
gactcccagctggggaatgcagacatggagatgactctggagcgagcagtgagtatgctc 
E A 0 H M P P SRI S A A A T F I I H E 
gaggcagaccacatgccgccatccaggatttctgctgcagctactttcat acgag • C F Q K SEA I K R V N Q L R GIL K L 
tgcttccagaaatctgaagctillaagagggttaaccagcttcgtggcatcctcaagctt • L Q L L K V Q NED v Q R A V eGA L R 
ctgcagctcctaaaagttcagaatgaagacgttcagcgagctgtgtgtggggccttgaga 
N L V F ED NON K L EV A E LNG V P 
aacttagtatttgaagacaatgacaacaaattggaggtggctgaactaaatggggtacct 
R L L Q v L K Q T R 0 LET K K Q lTD 
cggctgctccaggtgctgaagcaaaccagagacttggagactaaaaaacaaataacagac 
H T V N L R S R N G W P G A V A HAC N 
catacagtcaatttaagaagtaggaatggctggccgggcgcggtggctcacgcctgtaat 
PST L G G Q G G R I T R S G V R D Q P 
cccagcactttgggaggccaaggcgggcggatcacgaggtcaggagttcgagaccagcct 
D Q H G L L W N L S S N D K L K N L M I 
gaccaacatggtttgctgtggaatttgtcatctaatgacaaactcaagaatctcatgata 
TEA L L T L TEN I I I P F S G W P E 
acagaagcattgcttacgctgacggagaatatcatcatccccttttctgggtggcctgaa 
G D Y P K A N G L L D F D I F Y N V T G 
ggagactacccaaaagcaaatggtttgctcgattttgacatattctacaacgtcactgga 
C L R N M S SAG A D G R K A M R ReD 
tgcctaagaaacatgagttctgctggcgctgatgggagaaaagcgatgagaagatgtgac 
G LID S L V H Y V R G T I A D Y Q P D 
ggactcattgactcactggtccattatgtcagaggaaccattgcagattaccagccagat 
D KA T ENe V elL H N L S Y Q LEA 
gacaaggccacggagaattgtgtgtgcattcttcataacctctcctaccagctggaggca 
E L P E K Y S Q N I Y I Q N R N I Q T D 
gagctcccagagaaatattcccagaatatctatattcaaaaccggaatatccagactgac 
N N K S I G C F G S R S R K V K E Q Y Q 
aacaacaaaagtattggatgttttggcagtcgaagcaggaaagtaaaagagcaataccag 
D V P M PEE K S N P K G V E W L W H S 
gacgtgccgatgccggaggaaaagagcaaccccaagggcgtggagtggctgtggcattcc 
I V I R M Y L S L I A K S V R N Y T Q E 
attgttataaggatgtatctgtccttgatcgccaaaagtgtccgcaactacacacaagaa 
A S L GAL Q N L TAG S G P M P T S V 
gcatccttaggagctctgcagaacct c acggccggaagtggaccaatgccgacatcagtg 
A Q T V v Q K E S G L Q H T R K M L H V 
gctcagacagttgtccagaaggaaagtggcctgcag 
G D P S V K K T A I S L L 
cgaaagatgctgcatgtt 
R N L S R N L 
ggtgacccaagtgtgaaaaagacagccatctcgctgctgaggaatctgtcccggaatctt 
S L Q N E I A K E T L P D L V S I I P D 
tctctgcagaatgaaattgccaaagaaactctccctgatttggtttccatcattcctgac 
T V P S T 0 L L I E T T A SAC Y T L N 
acagtcccgagtactgaccttctcattgaaactacagcctctgcctgttacacattgaac 
N I I Q N S Y Q N A R 0 L L N T G G I Q 
aacataatccaaaacagttaccagaatgcacgcgaccttctaaacaccgggggcatccag 
K IM A I S A G DAY A S N K A S K A A 
aaaattatggccattagtgcaggcgatgcctatgcctccaacaaagcaagtaaagctgct 











861 Q F K K T 0 F V N S R T A KAY H S L K 
2581 cagtttaagaagacagattttgtcaacagccggactgccaaagcctaccactcccttaaa 
88 1 0 * 
2641 gactga 
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